News

Our January 2024 month-in-review spotlights some of our top coverage in nephrology, ranging from FDA news to clinical trial data and research about approaches to improving renal health.

These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.

Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.

A new proof-of-concept observation study reports the dual GLP-1/GIP agonist's positive efficacy and safety for adults with T1D.

Blood thinners added to clot-busting medication did not improve 90-day stroke outcomes, leading to early discontinuation of the MOST trial.

According to a new systematic review and meta-analysis, roxadustat's efficacy remains consistent across varying inflammation levels in patients with chronic kidney disease.

The FDA set its target action date for October, with this sNDA being supported by two phase 1 safety studies on AK patients.

This cohort study’s findings highlight the value of a smoking status assessment at the time of melanoma diagnoses.

Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.

This recap of top cardiology news from January 2024 spotlights pipeline updates, new guidance on peripheral interventions, and a celebration of what may be the single most impactful public health address in the history of the United States.

Testosterone replacement therapy did not differ significantly from placebo in preventing diabetes progression in a substudy of the TRAVERSE randomized trial.

These data indicate that in the US, the outpatient management of patients with pulmonary embolism identified as lower-risk may continue to be underutilized.

A study found 27.5% of individuals who had an emergency department for cannabis use were diagnosed with a new anxiety disorder within 3 years. However, only 5.6% of the general population developed a new anxiety disorder.

Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.

This analysis of trends in e-cigarette prevalence highlights several important trends among smokers, updating the current literature with new information about demographics and other data.

A new study found patients with schizophrenia on lurasidone had an effect size change of 0.33 on the PANSS prosocial subscale, suggesting improvements in social functioning.

Results of the systematic review and meta-analysis support the use of pan-genotypic DAA regimens for the treatment of chronic HCV in adolescents and children ≥ 3 years of age.

The FDA's acceptance of the NDA for acoramidis in ATTR-CM was announced on February 05, 2024 and assigns a November 2024 PDUFA for the agent.

Alirocumab every 2 or 4 weeks significantly reduced LDL-C in pediatric patients with inadequately controlled heterozygous familial hypercholesterolemia.

Long-term anti-VEGF treatment for nAMD was linked to a reduction in mortality risk, with a slight increase in CVD risk, across 16-years of follow-up in Denmark.

In new guidelines by the AAD, 18 new evidence-based recommendations and 5 practice statements were described for patients 9 years of age and older with acne.

A pooled analysis showed patients on cariprazine for major depressive disorder had only mild to moderate treatment-emergent adverse events.

Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.

The literature review discusses the rising incidence of eosinophilic esophagitis, highlighting the efficacy of proton pump inhibitors, challenges in diagnosis, and the need for collaborative decision-making in its management.

This segment of Eichenfield’s interview features a discussion about the recent announcement of a J-Code for the molluscum contagiosum treatment cantharidin.

Our January 2024 sleep month in review includes studies regarding periodic limb movements to link to cardiovascular disease and death, sleep apnea serving as a risk factor for uncontrolled, severe asthma, and more.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

The biosimilars month in review explores the efficacy and safety of biosimilars in treating uveitis, highlights the FDA’s acceptance of a biologics license application for an ustekinumab biosimilar, and emphasizes the safety and accessibility benefits of biosimilars in rheumatic conditions.